On Jun 30, 2021 female-founded startup Antheia closed a Series B round and raised $73,000,000 from Hillspire, Sherpalo Ventures, Viking Global Investors. The oversubscribed round was lead by Viking Global Investors.

About the company: Antheia is located in California, United States. The company is using synthetic biology to produce medicines currently sourced from plants. Antheia has already demonstrated success with its synthetic biology platform for complex pharmaceutical compounds. It has produced its first molecule, a KSM for a number of essential medicines, at commercially relevant titers in pilot scale runs (300L), and shown that the resulting material is chemically equivalent to that extracted from plants. The company has also demonstrated the biosynthesis of four major classes of plant-based medicines. 

Company website: www.antheia.bio/